World Diabetes Day

World Diabetes Day
Name	World Diabetes Day
Caption	Blue Circle for Diabetes
Observedby	United Nations, World Health Organization, International Diabetes Federation, Royal College of Physicians, American Diabetes Association
Date	14 November
Month	November
Frequency	Annual
Significance	Awareness of diabetes mellitus and its complications

World Diabetes Day is an annual international awareness day marked on 14 November to highlight the burden of diabetes mellitus, promote prevention and management, and advocate for policy action. Established by the International Diabetes Federation and World Health Organization in response to rising prevalence, the day mobilizes governments, health ministries, professional associations, patient groups, and private sector partners. Activities span clinical, policy, academic, and community settings, aiming to influence agencies such as the United Nations and regional bodies like the European Commission.

History

World Diabetes Day was created in 1991 by the International Diabetes Federation and the World Health Organization in recognition of the growing global burden of diabetes mellitus and the lack of public awareness. The date commemorates the birthday of Frederick Banting, who, with Charles Best, led work resulting in the discovery of insulin in 1921 at the University of Toronto, an achievement linked to institutions like Banting and Best Department of Medical Research and commemorated by awards such as the Nobel Prize in Physiology or Medicine. Early campaigns were supported by organizations including the Royal College of Physicians and American Diabetes Association, and later endorsed by the United Nations General Assembly when it recognized noncommunicable diseases in global policy discussions. Over decades the observance expanded through networks such as the Global Health Council, the World Medical Association, and regional groups like the Pan American Health Organization.

Objectives and Themes

The objectives set by the International Diabetes Federation and partners include raising awareness among policymakers in entities like the European Parliament and African Union Commission, improving access to essential medicines listed by the World Health Organization Model List of Essential Medicines, and promoting screening guidelines from bodies like the American Diabetes Association and International Society for Pediatric and Adolescent Diabetes. Annual themes have targeted issues endorsed by institutions such as UNICEF, World Bank, and World Trade Organization-adjacent health policy forums. Themes have addressed care for members of populations represented by groups like Médecins Sans Frontières, Red Cross, and Bill & Melinda Gates Foundation, focusing on prevention, detection, and equity in access to technologies such as continuous glucose monitoring and insulin pump therapy, with clinical guidance from the International Society for Clinical Densitometry and research insights from centers like Joslin Diabetes Center and Mayo Clinic.

Observance and Activities

Events organized by national federations, including Diabetes UK, Juvenile Diabetes Research Foundation, Canadian Diabetes Association, Australian Diabetes Society, and Indian Diabetes Federation involve public screenings, educational workshops, and public lectures featuring experts from institutions such as Harvard Medical School, Johns Hopkins University, University of Oxford, and Karolinska Institutet. Campaigns often feature the Blue Circle symbol promoted by the International Diabetes Federation and coordinated with health ministries like those of United Kingdom, United States Department of Health and Human Services, Government of India, and Health Minister of Brazil. Community events include city lighting initiatives in capitals like New Delhi, London, Washington, D.C., and Ottawa, partnerships with corporations such as Novo Nordisk, Eli Lilly and Company, Sanofi, and collaborations with advocacy groups including NCD Alliance and World Heart Federation.

Global Impact and Statistics

Epidemiological data cited by the International Diabetes Federation and World Health Organization indicate rising prevalence of type 2 diabetes across regions including South-East Asia Regional Office (WHO), African Region (WHO), and Americas (WHO). National surveillance systems in countries like China, India, United States, Brazil, and Mexico contribute data to global estimates alongside research from institutions such as Imperial College London and Australian Institute of Health and Welfare. Economic analyses by bodies such as the World Bank and Organisation for Economic Co-operation and Development assess direct and indirect costs, while clinical outcome studies from Cochrane Collaboration and National Institutes of Health report on complications like diabetic retinopathy, diabetic nephropathy, and cardiovascular disease. Public health campaigns reference WHO targets from documents similar to the Global Action Plan for the Prevention and Control of Noncommunicable Diseases.

Organization and Partners

Coordination is led by the International Diabetes Federation with technical collaboration from the World Health Organization and engagement from UN agencies such as United Nations Children's Fund and United Nations Development Programme. Key partners include non-governmental organizations like American Diabetes Association, Diabetes UK, Juvenile Diabetes Research Foundation International, Médecins Sans Frontières, research institutions such as Harvard School of Public Health, London School of Hygiene & Tropical Medicine, pharmaceutical companies including Novo Nordisk, Eli Lilly and Company, Sanofi, and foundations like the Bill & Melinda Gates Foundation and Wellcome Trust. Regional stakeholders include the African Diabetes Foundation, Asia Pacific Diabetes Policy Coalition, European Association for the Study of Diabetes, and national ministries of health from countries such as Canada, Japan, Germany, and South Africa.

Criticism and Challenges

Critics include academics from universities like Columbia University, University of California, San Francisco, and University of Sydney who highlight disparities in access to insulin and technologies, arguing that advocacy sometimes foregrounds corporate partners such as Novo Nordisk and Sanofi at the expense of low-cost public health solutions promoted by groups like People's Health Movement. Policy analysts at institutions like the Institute for Health Metrics and Evaluation and Chatham House note challenges in measuring impact across heterogeneous health systems in countries such as Nigeria, Pakistan, and Philippines. Debates involve trade-offs discussed in forums like the World Trade Organization and in publications from the Lancet and BMJ concerning intellectual property, pricing, and supply chains affecting insulin availability in regions including Sub-Saharan Africa, South Asia, and Latin America. Implementation challenges are highlighted by national diabetes programs in settings served by Pan American Health Organization and Southeast Asian Regional Office (WHO).

Category:Health awareness days